Mainolfi Nello 4
4 · Kymera Therapeutics, Inc. · Filed Dec 8, 2025
Insider Transaction Report
Form 4
Mainolfi Nello
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$2.08/sh+100,000$208,000→ 760,482 total - Sale
Common Stock
2025-12-08$89.17/sh−100,000$8,917,000→ 660,482 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-08−100,000→ 305,559 totalExercise: $2.08Exp: 2029-11-13→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.